<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02832700</url>
  </required_header>
  <id_info>
    <org_study_id>CGMPH2016</org_study_id>
    <nct_id>NCT02832700</nct_id>
  </id_info>
  <brief_title>Casein Glycomacropeptide in Healthy Subjects</brief_title>
  <official_title>Casein Glycomacropeptide in Healthy Subjects - Anti-inflammatory and Microbiome Modulating Effects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Arla Foods</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Casein glycomacropeptide (CGMP) has anti-inflammatory properties in experimental rodent
      colitis and using human in vitro inflammation models. Its use as a food ingredient has proven
      safe and with no influence on dietary intake. In a pilot study the investigators found, that
      orally administered CGMP seems to have a beneficial effect comparable to that of mesalazine
      in active distal ulcerative colitis.

      The investigators now wish to evaluate the effects in healthy subjects by studying the
      anti-inflammatory and microbiome modulating properties and by assessing possible changes in
      gastrointestinal symptoms.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">September 1, 2017</completion_date>
  <primary_completion_date type="Actual">September 1, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with reduction in high-sensitive C-reactive protein</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intestinal Microbiome</measure>
    <time_frame>4 weeks</time_frame>
    <description>Number of participants with changes in alpha-diversity in the fecal microbiome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with changes in FOXP3+ T-cells</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with decrease in TNF-alpha in stimulated peripheral blood mononuclear cells</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with changes in activation marker CD25+ in CD3+CD4+ T-cells</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with decrease in interferon-gamma in stimulated peripheral blood mononuclear cells</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with changes in activation marker CD69+ in CD3+CD4+ T-cells</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Compliance</measure>
    <time_frame>4 weeks</time_frame>
    <description>Number of participants with an average daily intake of above 75% of the intervention-product</description>
  </other_outcome>
  <other_outcome>
    <measure>Uptake of amino acids</measure>
    <time_frame>4 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Intestinal butyrate production</measure>
    <time_frame>4 weeks</time_frame>
    <description>Number of participants with increase in daily butyrate-production</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Gastrointestinal Disease</condition>
  <arm_group>
    <arm_group_label>Casein glycomacropeptide (CGMP)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During 4 weeks a daily oral intake of CGMP-protein-shake.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>During 4 weeks a daily oral intake of placebo-shake consisting of milk powder.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Casein glycomacropeptide</intervention_name>
    <arm_group_label>Casein glycomacropeptide (CGMP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Caucasians

          -  Body Mass Index 18.5-25.0

        Exclusion Criteria:

          -  Within 3 months: Acute intestinal disease (diarrhea more than 3 days in a week or
             bloody stools), hospital admission or antibiotic treatment.

          -  Chronic inflammatory disease or intestinal disease, including Crohn's disease,
             ulcerative colitis, celiac disease, rheumatoid arthritis or any other autoimmune joint
             disease, multiple sclerosis or any intestinal surgery apart from appendectomy.

          -  Pregnant or nursing.

          -  Unable to speak and understand Danish.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hendrik A Vilstrup, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>University of Aarhus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of medicine V (Hepatology and Gastroenterology)</name>
      <address>
        <city>Aarhus C</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2016</study_first_submitted>
  <study_first_submitted_qc>July 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2016</study_first_posted>
  <last_update_submitted>December 19, 2017</last_update_submitted>
  <last_update_submitted_qc>December 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glycopeptides</keyword>
  <keyword>dietary proteins</keyword>
  <keyword>whey protein</keyword>
  <keyword>caseinomacropeptide</keyword>
  <keyword>antiinflammatories</keyword>
  <keyword>human microbiome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Diseases</mesh_term>
    <mesh_term>Digestive System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Caseins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

